MEDIA RELEASES

Released in 2022

November 24 SQI Diagnostics Inc. Announces Private Placement of $1.0 Million
November 10 SQI Diagnostics Secures Up To $2 Million in FedDev Ontario Funding
October 19 SQI Diagnostics Extends Maturity Date of Pivot Credit Facility and Announces Deferral of Certain Interest Payments
October 17 Health Canada Approval of RALI-Dx
August 31 SQI Announces Grant of Stock Options 
August 29 SQI Diagnostics Reports Third Quarter 2022 Results
June 20 SQI Diagnostics extends maturity date of Pivot Credit Facility
June 17 SQI Diagnostics Inc. Announces Closing of $4.05 Million Debt Financing.
May 26 SQI Diagnostics Reports Second Quarter 2022 Results
April 13 SQI Diagnostics Extends Maturity Date Of Pivot Credit Facility
March 25 SQI Diagnostics Inc. to Participate in the 2022 Virtual Growth Conference
March 3 New York State Approves SQI Diagnostics’ EXACT COVID-19 Antibody Assay
February 28 SQI Diagnostics Reports First Quarter 2022 Results
February 14 SQI Diagnostics Completes Acquisition of Precision Biomonitoring’s Human Diagnostic Testing Business.
February 9 SQI Diagnostics Provides Update on Previously Announced Asset Purchase Transaction with Precision Biomonitoring Inc.
January 26 SQI Diagnostics – 2021 Annual Financial Results
January 24 SQI Diagnostics Inc Signs MOU with UK-Based Owlstone Medical
January 13 SQI Diagnostics Inc Congratulates its Partner UHN for Winning $24 Million Award from Government of Canada
January 10 SQI Enters Definitive Agreement to Acquire Precision Biomonitoring’s Human Diagnostic Testing Business
MEDIA RELEASES

Released in 2021

November 8 SQI Diagnostics Inc. Closes Second and Final Tranche of Private Placement
November 1 SQI Diagnostics Inc. Closes First Tranche of Private Placement with Insider Participation
September 24 SQI Diagnostics Inc. Announces Private Placement with Insider Participation
September 13 SQI Diagnostics Appoints Andrew Morris as Chief Executive Officer, and Grants Options
August 30 SQI Diagnostics Inc. Announces Grant of Stock Options
August 18 SQI Diagnostics Reports Third Quarter 2021 Results
July 23 FDA Stops Emergency Use Authorization Review of SQI Diagnostics RALI-Dx™ IL-6 Severity Triage Test for COVID-19 Patients
July 15 SQI Diagnostics and AZOVA sign distribution agreement to sell SQI’s COVID-19 HOME Antibody Test
June 15 SQI Diagnostics Inc. Announces $3.9 Million Funding via Warrant Exercise by Insiders
May 27 SQI Diagnostics Inc. Announces Grant of Stock Options
May 21 SQI Diagnostics Reports Second Quarter 2021 Results and Announces Departure of CEO and Appointment of Interim CEO
April 13 SQI Diagnostics and McMaster University Announce $900,000 Collaborative Research and Development Grant
April 1 SQI Diagnostics Submits RALI-Dx™ IL-6 Severity Triage Test for COVID-19 Patients to FDA for Emergency Use Authorization
March 8 SQI Diagnostics Receives $2.3 Million in Funds from Shareholder Exercise of Securities
March 1 SQI Diagnostics Reports First Quarter 2021 Results
February 18 SQI Diagnostics Announces New Corporate Website
February 10 SQI Diagnostics Announces Proposed Insider Sales and Warrant Exercises to Fund Company
January 27 SQI Diagnostics Reports Fourth Quarter and Fiscal 2020 Results
January 25 SQI Diagnostics Announces Patient Enrollment Begins for Its COVID-19 HOME Antibody Test Clinical Study